Patient description: The patient is a 24-year-old man who has had type 1 diabetes for 11 years. He presents to the emergency room with hyperglycemia and concern for possible diabetic ketoacidosis after not taking his insulin for 3 days. The patient reports that he is currently homeless and has lost his supply of insulin, syringes, glucometer, and glucose testing supplies. The patient states that at the time of his initial diagnosis with type 1 diabetes he was hospitalized with a glucose value >1000 mg/dL. At the time, he was experiencing polyuria, polydipsia, and polyphagia. He reports that he has been on insulin since the time of his diagnosis, and he has never been prescribed oral agents for diabetes management. Most recently, he has been using insulin glargine 55 units once daily, and insulin aspart sliding scale 3 times daily. The patient has had previous episodes of diabetic ketoacidosis, for which he was hospitalized. With this episode of hyperglycemia, he is not experiencing any nausea, vomiting, or abdominal discomfort, and he appears well. His lab studies showed: A1c: 11.3% Creatinine: 0.9 mg/dL with eGFR >60 mL/min Aspartate aminotransferase (AST): 17 U/L Alanine aminotransferase (ALT): 14 U/L Beta-hydroxybutyrate: 0.1 mmol/L Bicarbonate: 25 mEq/L Anion

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  Type 1 Diabetes Mellitus Diabetes Men and women between the ages of 18 and 60 years old, inclusive, at the time of screening Females of non-child bearing potential must be ≥1 year post-menopausal (confirmed by a serum follicle-stimulating hormone (FSH) levels ≥ 40 IU/mL) or documented as being surgically sterile. Females of child bearing potential must agree to use two methods of contraception Male subjects must be willing to use clinically acceptable method of contraception during the entire study Body mass index between 18.5 and 26.9 kg/m2, inclusive, at screening Diagnosed with Type 1 diabetes for greater than 2 years, based on clinical history or as defined by the current American Diabetes Association (ADA) criteria HbA1c ≥6.0 % but <9.0 % at screening Fasting C-peptide <0.2 ng/mL Current use of insulin pump and willing to use continuous glucose monitoring (CGM) system (e.g. DexCom) throughout the entire study ALT and/or AST within <1.5x ULN at screening Serum amylase and lipase within normal limits at screening  History or evidence of clinically-significant disorder or condition that, in the opinion of the Investigator, would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion Significant organ system dysfunction (e.g., clinically significant pulmonary or cardiovascular disease, anemia [Hemoglobin <10.0 g/dL], and renal dysfunction [eGFR <90 ml/1.73M2/min]) Any severe symptomatic hypoglycemic event associated with a seizure or requiring help from other people or medical facility in the past 6 months Current or recent (within 1 month of screening) use of diabetes medications other than insulin Use of steroids and/or other prescribed or over-the-counter medications that are known to affect the outcome measures in this study or known to influence glucose metabolism Smokes tobacco Known sensitivity to mammalian-derived drug preparations, recombinant protein-based drugs or to humanized or human antibodies History of illegal drug use or alcohol abuse within the last 6 months or a positive drug urine test result at screening History of pancreatitis, pancreatic neuroendocrine tumors or multiple endocrine neoplasia History of pheochromocytoma, or family history of familial pheochromocytoma